Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Patient Acceptance of Health Care × exemestane × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 199 Neoplasm Metastasis 19 Neoplasms 8 Breast Neoplasms, Male 6 Breast Diseases 5 Ovarian Neoplasms 4 Carcinoma, Intraductal, Noninfiltrating 4 Obesity 3 Endometrial Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Breast Carcinoma In Situ 3 Breast Cancer Metastatic 3 Recurrence 2 Prostatic Neoplasms 2 Neoplasms by Site 2 Multiple Endocrine Neoplasia Type 1 2 Carcinoma, Renal Cell 2 Bulbo-Spinal Atrophy, X-Linked 2 Arthralgia 2 Advanced Breast Cancer 2 Vitamin D Deficiency 1 Uterine Cervical Neoplasms 1 Tuberous Sclerosis 1 Triple Negative Breast Neoplasms 1 Thoracic Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Sleep Wake Disorders 1 Skin Diseases 1 Sexuality 1 Respiratory Tract Neoplasms 1

Interventions

palbociclib 1 exemestane 1 delta 24-sterol reductase 1 Vinorelbine 1 Therapeutics 1 Tamoxifen 1 Standard of Care 1 Risk Assessment 1 Paclitaxel 1 Letrozole 1 Influenza Vaccines 1 Fulvestrant 1 Focus Groups 1 Epirubicin 1 Drug Therapy 1 Counseling 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03355157 2024-10-01

PADMA

GBG Forschungs GmbH

Phase 4 Completed

Breast Neoplasms, Patient Acceptance of Health Care

Data powered by HemOnc (CC BY 4.0) Colophon ⚡